3 results
To demonstrate that crizotinib (Arm A) is superior to first-line chemotherapy, pemetrexed/cisplatin or pemetrexed/carboplatin (Arm B), in prolonging PFS in patients with advanced non-squamous NSCLC whose tumors harbor a translocation or inversion…
PRIMARY QUESTIONDuring the sentinel node procedure in breast cancer patients, does a 3D SPECT/CT protocol not lead to a longer operation time to remove axillary sentinel nodes, compared to the 2D standard protocol?• H0: OK-time(SPECT/CT) - OK-time(…
Primary objective* To study the antitumor activity and safety of crizotinib across predefined tumor types in patients whose tumors are harboring specific alterations in ALK and/or METSecondary objectives* To study the specificity of the kinase…